Clinical trials: Hepatic Malignancies
Primary Liver Cancer
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
- Trial name
- NCT03178929
- Testing
- S-Adenosyl Methionine
- Volunteers
- 207 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University
Hepatic Cancer, Hepatic Resection
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation
The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which…
- Trial name
- NCT06718153
- Testing
- Immunohistochemistry and in situ hybridisation analysis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus…
- Trial name
- NCT04619342
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency
- Trial name
- NCT03814005
- Testing
- Azacitidine, Pevonedistat
- Where
- 8 sites in United States, Spain
- Volunteers
- 17 people
- Sponsor
- Takeda
Breast Cancer
Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women
The project is imbued with the whole problematic of patient follow-up and patient support, taking into account the experiences and needs of breast cancer patients.
- Trial name
- Sav-AQ (NCT03472794)
- Testing
- web portal: " Mon réseau cancer du sein " ("My Breast cancer Network")
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with…
- Conditions
- Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
- Trial name
- NCT06682988
- Testing
- Mirvetuximab Soravtansine
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
Hepatic Veno-Occlusive Disease, Nephroblastoma
Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL
Hepatic veno-occlusive diseases (VOD) during cancer treatment in children are serious toxicities that have occurred with interruptions of chemotherapy and risk of relapse.
- Conditions
- Hepatic Veno-Occlusive Disease, Nephroblastoma, Acute Lymphoblastic Leukemia
- Trial name
- MVO (NCT04168788)
- Testing
- Blood test for genetic analysis
- Where
- 11 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Angers
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
IDH1-Mutated Malignancies
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
The objective of this study is to investigate the PK, PD, safety, and tolerability of ivosidenib in adult participants with IDH1-mutated malignancies and hepatic impairment (HI)/ renal impairment (RI).
- Trial name
- NCT07006688
- Testing
- Ivosidenib Oral Tablet
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 30 people
- Sponsor
- Servier Bio-Innovation LLC
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Hepatic Hemangioma, Liver Cancer
Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy
Our primary aim is to investigate whether perioperative remote ischemic conditioning (PRIC) as an adjunctive treatment can improve postoperative recovery in patients undergoing hepatectomy as an adjunct to standard treatment.
- Conditions
- Hepatic Hemangioma, Liver Cancer, Hepatolithiasis, Hepatectomy
- Trial name
- NCT06130436
- Testing
- Remote Ischemic Conditioning Once Daily, Remote Ischemic Conditioning Twice Daily
- Where
- China
- Volunteers
- 135 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
- Trial name
- NCT03035006
- Testing
- Lipotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Liposome Company
Neoplasm Metastasis, Liver Neoplasms
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
This clinical trial evaluated the safety and tolerability of CRS-100, an investigational agent containing a live-attenuated strain of Listeria monocytogenes (Lm).
- Conditions
- Neoplasm Metastasis, Liver Neoplasms, Carcinoma
- Trial name
- NCT00327652
- Testing
- CRS-100
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Anza Therapeutics, Inc.
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT05406206
- Testing
- Fruquintinib, Hepatic Arterial Infusion Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Cancers
HAI Abraxane With Gemcitabine and Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver, in combination with Gemzar® (gemcitabine) and Avastin® (bevacizumab) when given by…
- Trial name
- NCT01057264
- Testing
- HAI Abraxane, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignancies
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.
- Trial name
- NCT04831944
- Testing
- parsaclisib
- Where
- 5 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Colorectal Cancer
Combined Resection of Colorectal Metastases
This is a Phase II study of combined surgical resection for patients with both intra- and extra-hepatic metastases from colorectal cancer.
- Trial name
- CRC (NCT00606398)
- Testing
- surgical resection for patients with both intra- and extra-hepatic metastases
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Neuroendocrine Tumors
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has…
- Trial name
- NCT01469572
- Testing
- Pasireotide, Sir-sphere Radioembolization, Everolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.